Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating
Argus Raises Quest Diagnostics' Price Target to $163 From $155
Buy Rating Affirmed for Quest Diagnostics on Strong Earnings Visibility and Growth Prospects
Baird Adjusts Quest Diagnostics' Price Target to $144 From $138
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
Barclays: Maintaining the Quest Diagnostics (DGX.US) rating, adjusted from a wait-and-see shareholding rating to a shareholding wait-and-see rating, and the target price was adjusted from $138.00 to $144.00.
Quest Diagnostics Analyst Ratings
Citi: Maintains Quest Diagnostics (DGX.US) rating, adjusted from neutral to neutral, and adjusted the target price from $135.00 to $145.00.
Deutsche Bank Adjusts Quest Diagnostics Price Target to $136 From $125, Maintains Hold Rating
Quest Diagnostics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Tactile Systems Technology (TCMD) and Danaher (DHR)
Evercore ISI Raises Quest Diagnostics Price Target to $145 From $140
Quest Diagnostics: Strong Q1 Outperformance Spurs Buy Rating and Raised Full-Year Guidance
Barclays Remains a Hold on Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Truist Financial Sticks to Their Hold Rating for Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Piper Sandler Remains a Hold on Quest Diagnostics (DGX)
No Data